There are two parts to the answer to that question.
The first is that Canada has, through the support of provinces and territories, the pan-Canadian Pharmaceutical Alliance, which has existed since 2010. It reports that as of April 1, 2023, savings from the activities participating in public drug plans are estimated to be $3.89 billion annually.
With respect to the context of the bill itself, it refers to the development of a national bulk purchasing strategy advice coming from the Canadian drug agency. That, as yet, does not exist.